Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 13 to 15v39
  2. Study sites: 10 to 13v38
  3. Site contacts updated at 1 of 10 sitesv37
  4. Primary and study completion dates: Apr 2024 to Dec 2028v36 Show 4 more changesShow less
    • Enrollment target: 500 to 700
    • Site contacts updated at 1 of 10 sites
    • Collaborators: 1 to 2
    • Study title shortened, about 1 word
  5. Site contacts updated at 2 of 10 sitesv35
Show 33 earlier versionsHide 33 earlier versions
  1. Study sites: 8 to 10v34
  2. Site contacts updated at 2 of 8 sitesv33
  3. Site details revised at 1 of 8 sitesv32
  4. Primary and study completion dates: Apr 2020 to Apr 2024v31 Show 4 more changesShow less
    • Eligibility criteria shortened, about 83 words
    • Study description shortened, about 29 words
    • Site details revised at 3 of 8 sites
    • Collaborators: 3 to 1
  5. Study sites revised (8)
    • Study title shortened, about 4 words
    v30
  6. Primary and study completion dates: Apr 2019 to Apr 2020v29
  7. Re-verified, no change to tracked fieldsv28
  8. Site contacts updated at 1 of 8 sitesv27
  9. Site contacts updated at 1 of 8 sitesv26
  10. Site contacts updated at 3 of 8 sitesv25
  11. Site contacts updated at 1 of 8 sitesv24
  12. Enrollment target: 250 to 500
    • Site contacts updated at 1 of 8 sites
    v23
  13. Primary and study completion dates: Apr 2016 to Apr 2019
    • Site contacts updated at 2 of 8 sites
    v22
  14. Site contacts updated at 1 of 8 sitesv21
  15. Site contacts updated at 2 of 8 sitesv20
  16. Study sites: 9 to 8
    • Study description revised
    • Eligibility criteria expanded, about 3 words
    • Study title expanded, about 3 words
    v19
  17. Site details revised at 1 of 9 sitesv18
  18. Lead sponsor: Boston University to University of Pennsylvania
    • Study sites: 8 to 9
    v17
  19. Site contacts updated at 2 of 8 sitesv16
  20. Lead sponsor: Office of Rare Diseases (ORD) to Boston Universityv15 Show 6 more changesShow less
    • Enrollment target: 96 to 250
    • Primary completion date: Apr 2011 to Apr 2016
    • Study sites: 6 to 8
    • Study description shortened, about 6 words
    • Collaborators: 1 to 3
    • Eligibility criteria expanded, about 2 words
  21. Site contacts updated at 1 of 6 sitesv14
  22. Site contacts updated at 3 of 6 sitesv13
  23. Study sites: 5 to 6v12
  24. Primary completion date: Apr 2011
    • Study completion date: Apr 2016
    v11
  25. Re-verified, no change to tracked fieldsv10
  26. Study sites: 4 to 5v9
  27. Site contacts updated at 1 of 4 sitesv8
  28. Site details revised at 1 of 4 sitesv7
  29. Collaborators expanded, about 5 wordsv6
  30. Site details revised at 1 of 4 sitesv5
  31. Site details revised at 1 of 4 sitesv4
  32. Re-verified, no change to tracked fieldsv3
  33. Site contacts updated at 1 of 4 sitesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Trial Details
NCT Number NCT00315380
Lead Sponsor University of Pennsylvania
Collaborators: GlaxoSmithKline, AstraZeneca
Conditions
(from sponsor)		 Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Related terms Churg-Strauss Syndrome
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov